TruScreen Group Ltd (NZX: TRU) provides an opto-electrical technology-based real-time, low cost and portable system for the detection of cancer or pre-cancerous cells in cervical tissues. TRU’s disruptive technology is non-invasive for women and provides objective and fast screening, thus providing an efficient alternative to the conventional Pap smear test that requires collection of tissue samples from the cervix. We believe TRU is well-positioned to benefit from the rapid commercial roll-out of its devices in the low-and middle-income countries (LMICs), with a primary focus on China.